Mitochon Pharmaceuticals Mitochon Pharmaceuticals
  • Company
  • Science & Technology
  • Pipeline
  • News & Publications
  • Contact

Mitochon Pipeline

Compounds

MP101

Huntington’s Disease

Duchenne Muscular Dystrophy

Optic Neuritis

MP201

Multiple Sclerosis

Parkinson’s Disease

Pre-Clinical Efficacy

IND Enabling Activities

Phase I

Phase II

  • No Widgets

    "Secondary" needs some widgets.

  • Mitochon Pharmaceuticals Mitochon Pharmaceuticals
    • MP 201:
    • Optic Neuritis

    Optic Neuritis (pre-MS)

    • Inflammatory demyelinating disease of the optic nerve.
    • Either idiophathic or associated with multiple sclerosis.
    • Presentation: Acute unilateral vision loss.
      1. Progresses 1-2 weeks.
        Pain on eye movement.

    • Significant retinal ganglion cell (RGC) axonal loss occurs following optic neuritis.
    • Permanent vision loss from death of RGCs.
      1. Pain on eye movement.

    Optic Neuritis: Vision Loss

    • Acute vision loss from inflammation and demyelination .
      1. Improves when inflammation resolves.

    • Permanent vision loss from death of RGCs.
      1. No improvement after inflammation.

    OUR DATA SHOWS:
    MP201 prevents RGC loss during experimental optic neuritis.
    • Reduces demyelination without suppressing inflammation.
    • Preserves visual function. (Optokinetic Responses)
    Known effects on mitochondria and oxidative stress suggest common mechanism of neuroprotection.

    MP201 Prevents Retinal Ganglion Cell (RGC) Loss

    MP201 treatment attenuates RGC loss. Neuroprotective effects of MP201 were evaluated by counting RGCs immunolabelled with Brn3a antibody in 12 standardized fields, three from each quadrant of the retina. A. RGC loss in eyes of EAE mice (**p<0.01 vs control, N=10 eyes) is reduced by 16 mg/kg MP201 treatment from day 15 to 42 (p<0.001 vs EAE, N=10). 80 mg/kg MP201 also induces a significant (p<0.05 vs EAE, N=10) improvement in RGC numbers. B. Representative images show RGCs in one field of retina from each group (original magnification X20).

    MP201 Prevents Axonal Loss.

    MP201 treatment significantly reduces axonal loss in optic neuritis. Neurofilament staining was used to evaluate axonal loss in sections of optic nerves isolated at day 42 post-immunization. A. The optical density of neurofilament staining calculated from three equal sized fields from each optic nerve shows a significant decrease (***p<0.001) in optic nerves (N=10 nerves) from EAE mice compared to optic nerves (N=10) from control mice. Treatment with 16 mg/kg (@@@p<0.001, N=10) or 80 mg/kg (@@p<0.01, N=10).

    MP201 Prevents Demyelination.

    MP201 treatment attenuates demyelination in optic nerves during EAE. To examine whether MP201 treatment prevents demyelination, optic nerves were isolated from mice 42 days post-immunization, and were stained with LFB. A. LFB stained optic nerve longitudinal sections were examined by a blinded investigator and demyelination was quantified on a 0-3 point scale. optic nerves (N=10 nerves) from EAE mice had a significantly (**p<0.01) higher demyelination score compared to optic nerves (N=10) from control mice, and treatment with 16 mg/kg (@@p<0.01 vs EAE, N=10) or 80 mg/kg (@p<0.05 vs EAE, N=10) MP201 lead to a significant decrease in demyelination scores. B. A representative image of one optic nerve from a PBS-treated EAE mouse shows less LFB (blue) staining than an optic nerve from a control mouse, as well as optic nerves of EAE mice treated with either 16 mg/kg or 80 mg/kg MP201 (original magnification X20.
    Mitochon Pharmaceuticals, Inc.
    970 Cross Lane
    Blue Bell, PA 19422
    © 2021 Mitochon Pharmaceuticals, All Rights Reserved
    Website designed and managed by WP Cinch
    PageLines